We’ll get to today’s case in a moment, but first, a few words about SCOTUS and expiration dates. ..
One of our primary goals is to bring you the latest and greatest news in the drug and device litigation ..
Today’s guest post is by frequent contributor Dick Dean of the Tucker Ellis firm. This time, ..
Recently Rudy Giuliani was broiled for saying that the truth isn’t the truth. Denying a tautology ..
On the same day the Seventh Circuit overturned the verdict in Dolin v. GSK, the court handling the coordinated ..
This post is from the non-Reed Smith side of the blog. We haven’t talked about the district court decisions ..
In medical device product liability cases to which preemption by reason of FDA pre-market approval (“PMA”) ..
Today’s post is an update to our post from just a few weeks ago regarding McWilliams v. Novartis AG, No. 2:17-CV-14302 ..
It can sometimes be difficult for us here at the DDL Blog to address “mixed bag” cases. We are quite ..
When Justice Gorsuch was first nominated for the Supreme Court, we took a look at his preemption decisions ..
Being that it was the Sixth Circuit that allowed a failure-to-update claim to proceed against a generic ..
Today, on the last day of the United States Supreme Court’s 2018 Term, the Court issued an order granting ..
This post is from the non-Reed Smith side of the blog. What happens when a case involving a medical device ..
Today’s guest post is by Reed Smith associate Devin Griffin. It’s about preemption in a generic ..
This guest post is by Reed Smith associate Lora Spencer, who (as you might suspect) calls Texas her home. ..
Once again we find ourselves in the position of creating new defenses to a novel, plaintiff-side cause ..
Sure, it was enjoyable to read In re DePuy Orthopaedics, Inc., Pinnacle Hip Implant Product Liability ..
This post is from the non-Reed Smith side of the blog. It may be post Mardi Gras season, but we don’t ..
Not quite two years ago, the United States Supreme Court did something that we liked a lot – it abolished ..